source
- FDA requires GLP-1 drug labels to include warning about rare eye diseaseThe FDA has issued a directive to manufacturers of GLP-1 therapies, instructing them to revise product labeling. The label change must highlight an increased risk of a rare ocular condition that c…
- Phase 3 trial shows Zealand-Boehringer obesity drug survodutide does not raise cardiovascular death riskThe Phase 3 SYNCHRONIZE-CVOT study found that survodutide, the joint obesity therapy from Zealand and Boehringer Ingelheim, was non‑inferior to placebo for cardiovascular death, indicating no added…